PharmaMar (BME: PHM) stock: the official figures
PharmaMar (PHARMA MAR, S.A.) is listed on the Spanish stock exchange under the ticker PHM and belongs to the health care sector. In fiscal 2025 it reported revenue of €221.4m and a net profit of €75.0m, according to the annual accounts it filed with the regulator.
Identifiers for PharmaMar: LEI 959800QWKZ45ZQC2AV58.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | €221.4m | €174.9m | +26.6% |
| Operating profit | €60.7m | €6.5m | +838.7% |
| Net profit | €75.0m | €26.1m | +187.0% |
| Earnings per share | €4.30 | €1.49 | +188.6% |
| Operating margin | 27.4% | 3.7% | +23.7 pts |
| Net margin | 33.9% | 14.9% | +18.9 pts |
| Total assets | €395.1m | €349.6m | +13.0% |
| Equity | €251.8m | €208.4m | +20.9% |
| Cash | €17.8m | €63.2m | −71.8% |
| Operating cash flow | €53.1m | €6.0m | +781.5% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
7 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | €221.4m | €60.7m | €75.0m | €4.30 | Annual report |
| 2024 | €174.9m | €6.5m | €26.1m | €1.49 | Annual report |
| 2023 | €158.2m | −€3.8m | €1.1m | €0.06 | Annual report |
| 2022 | €196.3m | €44.1m | €49.4m | €2.73 | Annual report |
| 2021 | €229.8m | €92.4m | €92.9m | €5.14 | Annual report |
| 2020 | €270.0m | €155.9m | €137.3m | €7.50 | Annual report |
| 2019 | €85.8m | −€17.5m | −€11.4m | −€0.05 | — |
The full income statement, balance sheet and cash flow statement are in the annual accounts of PharmaMar. Year by year: revenue, net income and dividends paid. Half-year results and dividends are on the Spanish page, Acciones de PharmaMar.
Dividends
In fiscal 2025, PharmaMar paid €13.9m in dividends, 18.6% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | €13.9m | 18.6% |
| 2024 | €11.4m | 43.7% |
| 2023 | €11.7m | 1,028.1% |
| 2022 | €11.8m | 23.8% |
| 2021 | €10.9m | 11.7% |
| 2020 | €8.8m | 6.4% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about PharmaMar
- How much did PharmaMar earn in fiscal 2025?
- PharmaMar reported a net profit of €75.0m for fiscal 2025, on revenue of €221.4m. The year before it reported a net profit of €26.1m.
- Does PharmaMar pay a dividend?
- In fiscal 2025, PharmaMar paid €13.9m in dividends, 18.6% of its net profit, according to its cash flow statement.
- What are the earnings per share of PharmaMar?
- They were €4.30 in fiscal 2025, compared with €1.49 the year before.
- Where is PharmaMar listed?
- PharmaMar is listed on the Spanish stock exchange under the ticker PHM and belongs to the health care sector.
- Where do the figures for PharmaMar come from?
- From the report PharmaMar files every year in the European single electronic format (ESEF), the same one the CNMV, the Spanish regulator, receives. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the report PharmaMar files every year in the European single electronic format (ESEF), the same one the CNMV, the Spanish regulator, receives. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.